20.59

0.72% -0.15

After Hours: 20.62 0.03 +0.15%

Dianthus Therapeutics Inc (DNTH)

Overview News Price History Financials Discussions Forecast

Dianthus Therapeutics Inc stock is traded at $20.59, with a volume of 190.85K. It is down -0.72% in the last 24 hours and down -11.78% over the past month. Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.

Previous Close:

$20.74

Open:

$20.7

24h Volume:

190.85K

Relative Volume:

0.72

Market Cap:

$661.46M

Revenue:

$4.12M

Net Income/Loss:

$-56.68M

P/E Ratio:

-3.7147

EPS:

-5.5429

Net Cash Flow:

$-51.44M

1W Performance:

-5.98%

1M Performance:

-11.78%

6M Performance:

-26.73%

1Y Performance:

-22.13%

1-Day Range:

$20.30

$21.58

1-Week Range:

$20.00

$22.57

52-Week Range:

$18.34

$33.77

Dianthus Therapeutics Inc Stock (DNTH) Company Profile

Name

Dianthus Therapeutics Inc

Sector

Healthcare (1167)

Industry

Biotechnology (670)

Phone

929-999-4055

Address

7 TIMES SQUARE, NEW YORK

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

DNTH's Discussions on Twitter

Compare DNTH with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
DNTH Dianthus Therapeutics Inc	20.59	661.46M	4.12M	-56.68M	-51.44M	-5.5429
VRTX Vertex Pharmaceuticals Inc	512.52	131.61B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	672.36	73.51B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	619.97	37.67B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	253.44	32.81B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	266.26	28.62B	3.81B	-644.79M	-669.77M	-6.24

Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform
Jul-26-24	Initiated	Robert W. Baird	Outperform
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy
Feb-15-24	Initiated	Stifel	Buy
Dec-26-23	Initiated	Jefferies	Buy
Nov-22-23	Initiated	Wedbush	Outperform
Oct-30-23	Initiated	Guggenheim	Buy
Sep-28-23	Initiated	Raymond James	Outperform
Aug-25-22	Downgrade	Goldman	Buy → Neutral
Jan-06-22	Upgrade	Goldman	Neutral → Buy
Aug-20-21	Resumed	Goldman	Neutral
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral
Jul-22-21	Reiterated	B. Riley Securities	Buy
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight
Jun-15-21	Initiated	BTIG Research	Buy
May-18-21	Initiated	B. Riley Securities	Buy
Jan-07-21	Initiated	Mizuho	Buy
Jun-08-20	Upgrade	Goldman	Neutral → Buy
Mar-25-19	Downgrade	Goldman	Buy → Neutral
Mar-15-19	Initiated	Raymond James	Outperform

View All

Dianthus Therapeutics Inc Stock (DNTH) Latest News

12:33 PM

FY2025 Earnings Forecast for DNTH Issued By Lifesci Capital - MarketBeat

12:33 PM

Mar 18, 2025

Wedbush Equities Analysts Reduce Earnings Estimates for DNTH - MarketBeat

Mar 18, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 3.8%Here's Why - MarketBeat

Mar 18, 2025

Mar 17, 2025

HC Wainwright Reaffirms "Buy" Rating for Dianthus Therapeutics (NASDAQ:DNTH) - MarketBeat

Mar 17, 2025

Dianthus Therapeutics' (DNTH) Outperform Rating Reiterated at Wedbush - MarketBeat

Mar 16, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Shares Gap DownWhat's Next? - MarketBeat

Mar 16, 2025

Dianthus Therapeutics (DNTH) Projected to Post Quarterly Earnings on Thursday - MarketBeat

Mar 16, 2025

Mar 15, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat

Mar 15, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 5.5%Here's Why - MarketBeat

Mar 15, 2025

Dianthus Therapeutics (NASDAQ:DNTH) Issues Earnings Results, Beats Expectations By $0.04 EPS - MarketBeat

Mar 15, 2025

Research Analysts Set Expectations for DNTH Q1 Earnings - Defense World

Mar 15, 2025

Mar 14, 2025

HC Wainwright Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World

Mar 14, 2025

Guggenheim Reaffirms Buy Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World

Mar 14, 2025

Wedbush Reaffirms “Outperform” Rating for Dianthus Therapeutics (NASDAQ:DNTH) - Defense World

Mar 14, 2025

Mar 13, 2025

Dianthus Therapeutics' (DNTH) "Buy" Rating Reaffirmed at Guggenheim - MarketBeat

Mar 13, 2025

We're Not Very Worried About Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Rate - Yahoo Finance

Mar 13, 2025

Dianthus Therapeutics Full Year 2024 Earnings: Beats Expectations - Yahoo Finance

Mar 13, 2025

Dianthus Therapeutics (DNTH) to Release Quarterly Earnings on Thursday - Defense World

Mar 13, 2025

Dianthus Therapeutics Reports 2024 Financial Results and Clinical Progress - TipRanks

Mar 13, 2025

Mar 12, 2025

Stifel maintains Buy rating on Dianthus Therapeutics stock By Investing.com - Investing.com Canada

Mar 12, 2025

Dianthus Therapeutics shares fall as Q4 results miss expectations By Investing.com - Investing.com South Africa

Mar 12, 2025

Dianthus Therapeutics shares fall as Q4 results miss expectations - Investing.com India

Mar 12, 2025

Optimistic Buy Rating for Dianthus Therapeutics Driven by Promising DNTH103 Data and Pipeline Progress - TipRanks

Mar 12, 2025

Dianthus Therapeutics: Strong Financials and Promising Clinical Trials Justify Buy Rating - TipRanks

Mar 12, 2025

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Given Consensus Rating of “Buy” by Brokerages - Defense World

Mar 12, 2025

Mar 11, 2025